Bruce Linton
Board Director @ Definium Therapeutics
Ottawa, Canada
Bruce Linton is a post-ipo equity investor at Definium Therapeutics in Ottawa focused on Cannabis and Health Care. Mr. Linton is the founder of Canopy Growth Corporation (CGC) and co-founder of Tweed Marijuana Inc.Bruce’s primary focus has been to position cannabis brands in a competitive market and to raise the capital necessary to fund such operations. Bruce’s experience as a founder, CEO, and Board member across a wide variety of enterprises has influencedthe positive start of Canopy Growth, which to date has enjoyed market support for capital raises of over $150 million and the distinction of being the first company in the industry to be offered debt instruments by a federal lender. Bruce has led three M&A transactions valued over $500 million total since founding CGC. In addition to his leadership responsibility at Canopy Growth, Bruce is the CEO of communications company Martello Technologies. After beginning his career at Newbridge Networks Corporation, he has since held positions that include General Manager and Re-Founder of Computerland.ca, President and Co-Founder of webHancer Corp, and part of the establishing team at CrossKeys Systems Corporation. He was also part of the leadership team for the NASDAQ/TSX initial public offering at CrossKeys. Bruce has been responsible for the acquisition and/or disposition of over $600 million in business assets, and has established regular engagement with the World Bank and Asia Development Bank while focused on markets in India, Philippines, China, Peru, Colombia, Ecuador, Azerbaijan and Uzbekistan. He is the past Chairman of the Ottawa Community Loan Foundation, past Board Member and Treasurer of Canada World Youth past Board of Governor for Carleton University, past President of the Nepean Skating Club and past President of the Carleton University Students Association.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Bruce Linton invests in
Stages Bruce Linton invests in
Countries Bruce Linton invests in
Round sizes
Round size
- Seed
- $1.8M–$5M
- Post-IPO Equity
- $40k–$53M
Investment Focus
Industry
- Cannabis 3 (38%)
- Health Care 3 (38%)
- Biotechnology 3 (38%)
- Pharmaceutical 2 (25%)
- SaaS 1 (13%)
Stage
- Post-IPO Equity 4 (50%)
- Seed 2 (25%)
- Pre-Seed 1 (13%)
- Post-IPO Debt 1 (13%)
Country
- Canada 2 (25%)
- United States 2 (25%)
- Denmark 1 (13%)
- Germany 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SynBiotic
|
SynBiotic unlocks the power of cannabinoids to heal various diseases. They are consolidating the muscular player under one roof to make cannabinoids accessible. They treat chronic pain, stress, and sleep issues that affect health and well-being. | $2.5M / Post-IPO Equity / Oct 31, 2022 | |
Martello Technologies
|
Martello Technologies manages the performance of real-time services on complex distributed cloud networks. Their solutions, which include network performance management software as a service (SaaS) and SD WAN, allow over the top (OTT) service providers and enterprises around the world to deliver better service quality and a reliable userexperience. Designed for real-time communications, Martello’s solutions detect, identify and address network performance problems BEFORE service quality is impacted. | $37K / Post-IPO Debt / Mar 24, 2022 | |
|
Martello Technologies
|
Martello Technologies manages the performance of real-time services on complex distributed cloud networks. Their solutions, which include network performance management software as a service (SaaS) and SD WAN, allow over the top (OTT) service providers and enterprises around the world to deliver better service quality and a reliable userexperience. Designed for real-time communications, Martello’s solutions detect, identify and address network performance problems BEFORE service quality is impacted. | $39.9K / Post-IPO Equity / Mar 24, 2022 | |
Octarine Bio
|
Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | $1.8M / Seed / Nov 12, 2020 | |
Omura
|
Omura is a technology and design brand focused on the cannabis and wellness space, founded on the goal of perfecting the whole flower cannabis experience. The Omura system delivers a sustainable, sophisticated, and smoke-free experience for the purest method of cannabis consumption. Next-generation ‘heat not burn’ technology elevates the wholeflower dosing experience, giving users a clean, safe, and convenient whole flower experience. With precision engineering, Omura is pioneering the evolution of cannabis through their proprietary vaporizer system that is now available in California and Arizona. | $5M / Seed / Apr 27, 2020 | |
Definium Therapeutics
|
Definium Therapeutics provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. | $6M / Post-IPO Equity / Sep 30, 2019 | |
TerrAscend
|
TerrAscend is a vertically-integrated Canadian cannabis company that strives to create and deliver quality products and services that meet the evolving needs of the cannabis market. It provides support to patients through its wholly-owned subsidiaries, Solace Health Inc., a licensed producer of cannabis under the Access to Cannabis for MedicalPurposes Regulations, and Terra Health Network Inc., a provider of clinical support and education programs led by health care professionals. TerrAscend offers prescription cannabinoids and medical cannabis solutions for patients suffering from chronic pain and debilitating illnesses and focuses on drug research and development, cannabis devices, delivery systems, and hemp health products. | $52.5M / Post-IPO Equity / Nov 15, 2017 | |
|
Octarine Bio
|
Octarine Bio is a synthetic biology company that produces superior cannabinoids for the pharmaceutical industry. | Pre-Seed |
Co-Investors
Oskare Capital
2 deals together
Wesley Clover
2 deals together
BT Growth Capital
1 deal together
RIV Capital
1 deal together
JW Asset Management
1 deal together
Vaekstfonden
1 deal together
About Definium Therapeutics
Definium Therapeutics provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.
Definium Therapeutics Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Bruce Linton
Board Director
|
|||
Bradford Cross
Chief Technology Officer
|
|||
Daniel Karlin
Chief Medical Officer
|
|||
Francois Lilienthal
Chief Commercial Officer
|
|||
Javier Muniz
VP of Research & Development Strategy
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Bruce Linton invest in?
Bruce Linton invests primarily in Cannabis, Health Care and Biotechnology startups, most often at Post-IPO Equity and Seed stage. Most of the 8 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Bruce Linton's check size?
Bruce Linton typically joins rounds of $1.8M–$5M at Seed and $40k–$53M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Bruce Linton participates in.
When did Bruce Linton last invest?
The most recent investment recorded for Bruce Linton closed in Oct 2022. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
